BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/19/2023 10:19:33 AM | Browse: 114 | Download: 142
 |
Received |
|
2022-12-28 22:16 |
|
Peer-Review Started |
|
2022-12-28 22:17 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-21 05:52 |
|
Revised |
|
2023-03-06 23:57 |
|
Second Decision |
|
2023-04-18 02:58 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-18 08:11 |
|
Articles in Press |
|
2023-04-18 08:11 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-06-09 09:40 |
|
Publish the Manuscript Online |
|
2023-06-19 10:19 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Opinion Review |
| Article Title |
Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jessica Hellings |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jessica Hellings, MD, MMed, Professor, Department of Psychiatry, University of Missouri-Kansas City, 300 SE Second St, Lee's Summit, MO 64063, United States. jessica.hellings@uhkc.org |
| Key Words |
Autism; Pharmacotherapy; Dextroamphetamine; Loxapine; Amitriptyline; Minimally verbal; Neurotrophic |
| Core Tip |
Most prescribing in autism spectrum disorders (ASD) is off-label; only risperidone and aripiprazole are Federal Drug Administration-approved in ASD, for irritability. Atypical antipsychotics are associated with metabolic side effects. Loxapine at 5-10 mg/day resembled an atypical antipsychotic in positron emission tomography studies; preliminary studies and clinical experience in ASD suggest efficacy and a promising metabolic profile. Controlled attention deficit hyperactivity disorder (ADHD) medication trials in ASD youth include methylphenidate, atomoxetine and guanfacine. The author recommends dextroamphetamine as an important treatment option for ADHD in ASD. Amitriptyline often improves impulsive aggression, self-injury, sleep, anxiety and enuresis. This article recommends additional older drug trials in ASD: Detroamphetamine, amitriptyline, loxapine, and lamotrigine for likely seizures. |
| Publish Date |
2023-06-19 10:19 |
| Citation |
Hellings J. Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials. World J Psychiatry 2023; 13(6): 262-277 |
| URL |
https://www.wjgnet.com/2220-3206/full/v13/i6/262.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v13.i6.262 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
